In addition, although DZNep inhibits sphere-formation of BRCA1-deficient tumor cells and considering the role of EZH2 in stem cells and cancer [43], in vivo studies will be required to determine whether targeting of EZH2 by itself or in combination with other treatments can result in complete eradication of the tumor. This evidence concerns the gene EZH2 and cancer.